Search Results
Your search for Richard L. Schilsky, MD, FASCO matches 119 pages
Showing 101 - 119New ASCO Study Aims to Learn From Patient Access to Targeted Cancer Drugs Used Off-Label
ASCO plans to launch a first-ever study that will offer cancer patients access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes to help oncologists learn the best uses of these drugs outside of approved indications. “One of the major challenges to implementing ...
Friends of Cancer Research Holds Annual Conference on Clinical Cancer Research
Friends of Cancer Research, in conjunction with the Engelberg Center for Health Care Reform at Brookings, recently held the seventh annual Conference on Clinical Cancer Research in Washington, DC. The panels that comprised the daylong meeting discussed a future that has already begun. The most...
ASCO Releases Annual Report on Progress Against Cancer
ASCO recently released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). The report credited improvements in CLL care with four...
Molecular Oncology Tumor Boards Invite Discussion of Growing Field in Cancer Care
Oncologists and other related health-care providers now have an online platform for the discussion of the growing area of tumor molecular profiling tests and studies. In January, ASCO launched the Molecular Oncology Tumor Boards, a series of monthly user-driven discussions designed to help...
ASCO Commends Margaret Hamburg, MD, for Leadership as FDA Commissioner
ASCO expresses deep gratitude to Margaret Hamburg, MD, for her 6 years of vision and progress as Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Hamburg, one of the longest-serving FDA commissioners, leaves a legacy of important advances in regulatory science and medicine. The...
ASCO Collaborates in Launch of Crowd-Sourced Molecular Oncology Tumor Board Series
The ASCO University®, the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) recently announced their collaboration to create the Molecular Oncology Tumor Board series, an online and user-driven resource designed to help cancer care providers with the...
ASCO Commends Dr. Varmus for Outstanding Leadership
Following news of Dr. Varmus’ planned departure from the National Cancer Institute (NCI), ASCO issued the following statement: ASCO is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute [NCI]. During Dr. Varmus’ tenure, the...
ASCO Expresses Concern Over New Oncology Care Model
While commending the Centers for Medicare & Medicaid Services (CMS) for seeking new approaches to physician payment, ASCO expressed concerns over the model’s limited scope. “We are disappointed [CMS has] chosen to pursue only one model—and one that continues to rely on a broken fee-for-service...
ASCO Releases 2015 Report on The State of Cancer Care in America
In March, ASCO published its second annual report, The State of Cancer Care in America: 2015.1 Its findings show a mixed landscape, on the one hand, spotlighting advances in therapy and improving survival rates, but on the other, describing a cancer care system under stress from increasing demand...
Creating a Collective Path Forward to Optimize Value in Cancer Care
The Centers for Medicare and Medicaid Services projects that U.S. health-care spending will reach $4.3 trillion and account for 19.3% of the nation’s gross domestic product by 2019.1 Although cancer care represents a small fraction of overall health-care costs, the cost of cancer care is rapidly...
ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug...
Precision Medicine Trials Bring Targeted Treatments to More Patients
At the 2015 ASCO Annual Meeting, both ASCO and the National Cancer Institute (NCI) unveiled details of new precision medicine trials that will greatly expand the number of patients with cancer who are benefiting from targeted agents. The trials will match a patient’s tumor molecular profile with an ...
Community Research Forum Holds 2015 Annual Meeting, Explores Developments and Strategies in Conducting Clinical Research
ASCO’s Community Research Forum (CRF) held its 2015 Annual Meeting September 20–21 at ASCO Headquarters in Alexandria, Virginia. Over 75 physician investigators, program directors, and research staff attended the meeting, representing a wide range of community-based practices and research sites...
Congress Passes Continuing Resolution, Research Funding Dips Slightly
On September 30, Congress passed a Continuing Resolution that will fund the government at current levels through December 11. Funding for both the National Institutes of Health (NIH) and the National Cancer Institute (NCI) dipped slightly as part of a 0.21% cut to all nondefense discretionary...
ASCO Launches TAPUR to Assess the Off-Label Use of Targeted Therapies for Patients With Advanced Cancers
Two years ago, Richard L. Schilsky, MD, FACP, FASCO, Chief Medical Officer of ASCO, proposed a unique clinical trial concept during an educational session on the challenges of delivering precision medicine services in a community setting at ASCO’s Annual Meeting. The idea was to design a clinical...
Applications Open for ASCO’s New Policy Fellowship Program
On October 15, ASCO launched a new fellowship program aimed at providing physicians with the necessary skills to shape cancer policy. ASCO is actively recruiting oncologists in the early phase of their careers that have leadership, civic, policy, or advocacy experience, and a keen interest in...
TAPUR: ASCO’s First Clinical Trial Addresses Critical Gaps in Understanding of and Access to Targeted Therapies
ASCO is preparing to expand the boundaries of precision medicine with the launch of its first clinical trial. At a press briefing during the 2015 ASCO Annual Meeting, the Society formally announced its plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study. At a time when...
ASCO 2015: ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and...
ASCO Releases Annual Report on Progress Against Cancer and Names the Cancer Advance of the Year
ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer, today, and for the first time announced its cancer Advance of the Year: gains made in the treatment of chronic lymphocytic leukemia (CLL). ASCO credits the improvements in CLL care with the...
